期刊
DIGESTIVE DISEASES AND SCIENCES
卷 66, 期 9, 页码 3192-3198出版社
SPRINGER
DOI: 10.1007/s10620-020-06618-3
关键词
SARS-CoV-2; Acute liver injury; Outcomes; NAFLD
资金
- AASLD Clinical, Translational and Outcomes Research Award
- NIH Training Grant in Epidemiology and Health Services [T32DK062708]
In a cohort study of 342 patients, metabolic diseases were highly prevalent with nearly 90% of patients being overweight. HS was associated with increased transaminitis and the need for intubation, dialysis, and vasopressors. However, there was no association between HS and jaundice or portal hypertensive complications. In sensitivity analysis including only patients with liver imaging > 30 days before onset of COVID-19, hepatic steatosis remained associated with disease severity and the risk of transaminitis.
Background Coronavirus disease-2019 (COVID-19) is a global pandemic. Obesity has been associated with increased disease severity in COVID-19, and obesity is strongly associated with hepatic steatosis (HS). However, how HS alters the natural history of COVID-19 is not well characterized, especially in Western populations. Aims To characterize the impact of HS on disease severity and liver injury in COVID-19. Methods We examined the association between HS and disease severity in a single-center cohort study of hospitalized COVID-19 patients at Michigan Medicine. HS was defined by either hepatic steatosis index > 36 (for Asians) or > 39 (for non-Asians) or liver imaging demonstrating steatosis > 30 days before onset of COVID-19. The primary predictor was HS. The primary outcomes were severity of cardiopulmonary disease, transaminitis, jaundice, and portal hypertensive complications. Results In a cohort of 342 patients, metabolic disease was highly prevalent including nearly 90% overweight. HS was associated with increased transaminitis and need for intubation, dialysis, and vasopressors. There was no association between HS and jaundice or portal hypertensive complications. In a sensitivity analysis including only patients with liver imaging > 30 days before onset of COVID-19, imaging evidence of hepatic steatosis remained associated with disease severity and risk of transaminitis. Conclusions HS was associated with increased disease severity and transaminitis in COVID-19. HS may be relevant in predicting risk of complications related to COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据